Welcome Guest
Home » Reports » Non-Invasive Cancer Diagnostics Market, 2015 - 2030

Non-Invasive Cancer Diagnostics Market, 2015 - 2030

Published: Oct 20, 2015
Pages: 229
Product Code: RA10048
License Type :  (Learn More)

Cancer is an extremely complex disease and medical science is still struggling to figure out the reasons and factors influencing the disease origin, propagation, spread (metastasis) and relapse. In addition to satisfying the unmet market need for advanced and efficient treatment interventions, cancer prevention, early detection and management is extremely important. The high cancer mortality rate is primarily due to delay in detection of the disease.Early diagnosis and screening makes it possible to cure the disease completely and/or increase survival rates.Over the years, various technological advances have helped medical professionals understand cancer better. Recent research in cancer biology has led to a lot of innovation in the development of a number of new diagnostic tools. These modern diagnostic techniques can help detect and classify cancer with increased accuracy and sensitivity.

 

It is also important to highlight that the cost of management and treatment of cancer is a growing concern considering its highly progressive and fatal nature.Performing a biopsy includes costs associated with the equipment, cost of the procedure itself, consultation fees, hospital fees, costs of analyticaltests and those associated with post-operative care.To manage this financial burden, the introduction of novel non-invasive techniques, which are cost-effective and more accurate, has become an indispensable necessity.

 

There are several advanced approaches, which are non-invasive or minimally invasivein nature, and these outweigh the limitations posed by invasive diagnostic procedures.Specifically, liquid biopsy has emerged as a promising non-invasive cancer diagnostic tool for early detection as well as monitoring the disease’s progress. This technique of tracing the presence of circulating biomarkers in blood and other biological fluids of cancer patients is becoming increasingly popular in the medical fraternity.In addition to liquid biopsy, the market is gradually witnessing the emergence of several other non-invasive diagnostic technologies. These include techniques based on molecular imaging, advanced genomic and transcriptomic methods of detection of clinically significant biomarkers and identification of nucleosomal levels. All such non-invasive tests hold a significant promise to enhance the quality of patient care. 

 

  • Synopsis
  • Table of
    Contents
  • List of
    Figures
  • List of
    Tables
  • Listed Companies
  • Sample
    Pages
  • Download Brochure

 

The ‘Non-Invasive Cancer Diagnostics Market, 2015-2030’ report provides an extensive study on liquid biopsy kits/assays that are either commercialised or under development for the diagnosis of different types of cancer. Liquid biopsy primarily focuses on the detection, isolation and characterisation of biomarkers from circulating tumour cells (CTCs), circulating tumour DNA (ctDNA) or exosomes present in biological fluids, which can be collected in a single blood draw. The market is characterised by the presence of several companies that have proprietary technologies/platforms for either isolation/enrichment/enumeration of CTCs or molecular characterisation/sequencing of the genetic material extracted from the CTCs/exosomes. Based on these platforms, a number of liquid biopsy kits and systems are being developed for non-invasive diagnosis, prognosis, patient and recurrence monitoring. It is important to stress that even though liquid biopsy has still not made a strong foothold in the field of oncology, it is likely to transform the cancer diagnostics market with many commercial success stories in the near future.

 

In addition to liquid biopsy, there are several other novel and promising non-invasive diagnostics being developed for the diagnosis and prognosis of cancer. However, these tests are only indicative of the disease and may require further validation through more robust diagnostic methods such as biopsy. These tests retrieve the test sample non-invasively and use innovative techniques to screen for the desired parameters indicative of the disease with a moderate level of accuracy. Some of these are designed to be used at home by the patient itself.

 

As companies continue to initiate and expand their research programs and platforms in this area, one of the key objectives outlined for this report is to understand the future potential of the market. This is done by analysing:

  • The global burden of cancer in terms of incidence and prevalence of different cancer indications across different geographies. 
  • The overall landscape of liquid biopsies and other novel diagnostic tests with respect to the type of analysis (CTCs/ctNA/exosomes), test sample source (blood/urine/others) and indications.
  • The likely global evolution of the liquid biopsy market taking into account initial diagnosis, recurrence monitoring and patient monitoring.
  • Contribution of other novel diagnostic tests in the non-invasive cancer diagnostics market and the market opportunity of the key indications influencing the overall growth.

 

We have provided three market forecast scenarios for the time period 2015-2030. The conservative, base and optimistic scenarios represent three different tracks of industry evolution. Our opinions and insights, presented in this study, were influenced by discussions that we conducted with experts in this area. All actual figures have been sourced and analysed from publicly available information and discussions with industry experts. The figures mentioned in this report are in USD, unless otherwise specified.

 

 

Example Highlights

  1. We have identified over 50 liquid biopsy tests; some of these are commercialised and the rest are currently under development. Of these, 50% tests are based on the identification of disease biomarkers in ctDNA of the test sample. Nearly 37% of the tests are based on the enumeration/analysis of CTCs in the sample and the remaining 13% validate the presence of the disease from the information obtained from exosomes.
  2. Several companies are developing systems and instruments to support the detection, isolation and characterisation of rare cells. Examples include (in no specific order) the Parsortix System by ANGLE, ScreenCell® Isolation Devices by ScreenCell, ApoStream™ System by ApoCell, ClearCell FX® System by ClearbridgeBioMedics and  iCellate® Instrument by iCellate Medical.
  3. Firms have also taken initiatives and entered into collaborations to co-develop liquid biopsy companion diagnostic products; notable examples include collaborations between Tokai Pharmaceuticals and Qiagen, AstraZeneca and Qiagen, SysmexInostics and Bayer HealthCare.
  4. In addition to liquid biopsy, we have identified close to 40 other non-invasive cancer diagnostics that are used for screening, diagnosis, prognosis and patient monitoring; these include techniques based on molecular imaging, advanced methods of detecting clinically significant biomarkers and identification of nucleosomal levels.
  5. Primarily driven by liquid biopsy, the non-invasive cancer diagnostics market is anticipated to grow aggressively ata healthy annual growth rate of 44% between 2015 and 2030. Prostate cancer, breast cancer, colorectal cancer and lung cancer are likely to be the key indications which will drive the market; combined, these are expected to account for over 70% of the total liquid biopsy market in 2030.

 

 

Research Methodology

Most of the data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

 

The secondary sources of information include

  • Annual reports
  • Investor presentations
  • SEC filings
  • Industry databases
  • News releases from company websites
  • Government policy documents
  • Industry analysts’ views

 

While the focus has been on forecasting the market over the coming ten years, the report also provides our independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

 

 

Chapter Outlines

Chapter 2 presents an executive summary of the report. It offers a high level view on where the market for liquid biopsy and other novel non-invasive diagnostics is headed in the mid to long term.

 

Chapter 3 provides a general introduction to cancer statistics and burden of the disease worldwide. In this section, we have also highlighted the importance of early detection of the disease through diagnosis and asymptomatic screening. The chapter outlines the conventional invasive diagnostic tests, which are widely used for cancer diagnosis and prognosis.

 

Chapter 4 discusses in detail the need for non-invasive cancer diagnostics and their importance. We have highlighted the underlying concept of liquid biopsy and other non-invasive tests. In addition, we have mentioned the principle behind common imaging tests that are deployed in cancer diagnosis.

 

Chapter 5 provides a holistic view of the non-invasive cancer diagnostics landscape. It enlists the liquid biopsy tests, technologies and systems. In addition, it offers a list of other non-invasive tests. These lists include information on the developer, technology used by the product, test sample source and indication. We have also mapped the geographical presence of the enlisted non-invasive cancer diagnostics developers.

 

Chapter 6 offers a comprehensive discussion on liquid biopsy. We have talked about the emerging need for liquid biopsy highlighting its advantages and challenges. In addition, we have provided technology profiles and product profiles of several liquid biopsy products. The chapter also mentions the liquid biopsy companion diagnostics, which are being co-developed as part of strategic collaborations.

 

Chapter 7 provides an overview of the other novel non-invasive diagnostics used in oncology. It highlights the different imaging based diagnostic procedures, biomarker and nucleosome based diagnostics, skin lesion and breath based diagnostics. The diagnostic procedures discussed in this chapter are backed up by several examples.

 

Chapter 8 highlights the market forecast and sizing of the overall non-invasive cancer diagnostics market. This chapter discusses, in detail, the parameters likely to influence the evolution of liquid biopsy market. In addition, we have also presented the market share of other non-invasive diagnostic tests and an opportunity analysis for the key indications likely to have the maximum impact on the overall market.

 

Chapter 9 provides detailed company profiles of the leading players in the market involved in the development of liquid biopsy as well as other non-invasive tests. Amongst other details, each profile includes information such as the company overview, financial performance, product portfolio and recent collaborations.

 

Chapter 10 summarises the overall report. In this chapter, we list the key takeaways and provide our independent opinion based on the research and analysis described in previous chapters.

 

Chapter 11 is a collection of interview transcripts of the discussions that were held during the course of this study.

 

Chapter 12 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.

 

Chapter 13 is an appendix, which provides the list of companies and organisations mentioned in the report.

 

 
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
 
2. EXECUTIVE SUMMARY
 
3. INTRODUCTION
3.1. Chapter Overview
3.2. Cancer Statistics and Burden of the Disease
3.3. Importance of Early Detection in Cancer
3.4. Detecting Cancer: Screening versus Diagnosis
3.5. Conventional Invasive Cancer Diagnostic Tests
3.5.1. Biopsy
3.5.2. Endoscopy
3.6. Need for Non-Invasive Approaches
 
4. CONCEPT OF NON-INVASIVE CANCER SCREENING AND DIAGNOSTICS
4.1. Chapter Overview
 
4.2. Diagnostic Imaging
4.2.1. Magnetic Resonance Imaging (MRI)
4.2.2. Mammography
4.2.3. Bone Scan
4.2.4. Computerised Tomography (CT) Scan
4.2.5. Integrated PET-CT Scan
4.2.6. Ultrasound
4.2.7. Barium Enema
 
4.3. Screening Assays
4.3.1. Pap Test and HPV Test
4.3.2. Tumour Marker Tests
4.3.3. Faecal Occult Blood Tests (FOBT)
4.3.4. Digital Rectal Exam (DRE)
4.3.5. MUGA Scan
 
4.4. Advanced Non-Invasive Approaches
4.4.1. Liquid Biopsy
4.4.2. Cytogenetic/Gene Expression Studies
4.4.3. Molecular Signature Based Non-Invasive Methods
4.4.4. Saliva-Based Oral Cancer Diagnostics
4.4.5. Vital Staining
4.4.6. Optical Biopsy
4.4.7. Other Techniques
 
5. MARKET OVERVIEW
5.1. Chapter Overview
 
5.2. Liquid Biopsy: Market Landscape
5.2.1. Liquid Biopsy: Distribution by Type of Analysis
5.2.2. Liquid Biopsy: Distribution by Sample Source
5.2.3. Liquid Biopsy: Distribution by Indication
5.2.4. Liquid Biopsy: Distribution by Region
5.3. Liquid Biopsy Technologies and Systems/Instruments
 
5.4. Other Non-Invasive Cancer Diagnostic Tests: Market Landscape
5.4.1. Other Non-Invasive Tests: Distribution by Sample Source
5.4.2. Other Non-Invasive Tests: Distribution by Indication
5.4.3. Other Non-Invasive Tests: Distribution by Region
 
6. LIQUID BIOPSY: DETAILED OUTLOOK
6.1. Chapter Overview
6.2. Non-Invasive Detection of Cancer over Biopsies
6.3. Circulating Biomarkers for Cancer
6.3.1. CTCs and ctcDNA
6.3.2. ctDNA
6.3.3. Exosomes
 
6.4. Liquid Biopsy Based Technology, Systems and Tests
6.4.1. ApoStream® Technology and ApoStream® CTC Test (ApoCell)
6.4.1.1. Overview
6.4.1.2. Results
6.4.1.3. Collaborations
6.4.1.4. Funding
 
6.4.2. BioFluidica CTC Isolation Technology and CTC Analysis System (BioFluidica/Roche)
6.4.2.1. Overview
6.4.3.2. Results
6.4.3.3. Collaborations
 
6.4.3. CELLSEARCH® System and CELLSEARCH® CTC Test (Janssen Diagnostics)
6.4.3.1. Overview
6.4.3.2. Results
6.4.3.3. Collaborations
6.4.3.4. Other Developments
 
6.4.4. LiquidBiopsy® Rare Cell Isolation Platform and ClearID Test (CynvenioBiosystems)
6.4.4.1. Overview
6.4.4.2. Collaborations
6.4.4.3. Other Developments
6.4.4.4. Funding
 
6.4.5. Parsortix System (ANGLE)
6.4.5.1. Overview
6.4.5.2. Results
6.4.5.3. Collaborations
6.4.5.4. Funding
 
6.4.6. QuantiGene® ViewRNA CTC Platform and Assay (Affymetrix)
6.4.6.1. Overview
6.4.6.2. Collaborations
 
6.4.7. IVDxTx Platform Technology and IVD CTC Assays (IVDiagnostics)
6.4.7.1. Overview
6.4.7.2. Collaborations
6.4.7.3. Other Developments
6.4.7.4. Funding
 
6.4.8. iCellate® (iCellate AB)
6.4.8.1. Overview
6.4.8.2. Collaborations
 
6.5. Liquid Biopsy and Companion Diagnostic Products
6.5.1. Tokai Pharmaceuticals and Qiagen
6.5.2. AstraZeneca and Qiagen
6.5.3. SysmexInostics and Bayer HealthCare
 
7. OTHER NOVEL NON-INVASIVE TECHNOLOGIES
7.1. Chapter Overview
7.2. Imaging Based Diagnostics
7.3. Biomarker and Nucleosome Detection
7.4. Skin Lesion Based Diagnosis
7.5. Diagnostic Breath Testing
 
8. MARKET SIZING AND FORECAST
8.1. Chapter Overview
8.2. Methodology
8.3. Overall Non-Invasive Cancer Diagnostic Market
8.4. Liquid Biopsy Market
8.4.1. Initial Diagnosis
8.4.2. Recurrence Monitoring
8.4.3. Patient Monitoring
8.4.4. Market Forecast Projections, 2015-2030
8.5. Opportunity Analysis for Important Indications
8.5.1. Prostate Cancer
8.5.2. Breast Cancer
8.5.3. Colorectal Cancer
8.5.4. Lung Cancer
8.6. Non-Invasive Cancer Diagnostics Market: Regional Distribution
 
9. COMPANY PROFILES
9.1. Chapter Overview
9.2. Companies with Focus on Liquid Biopsy
9.2.1. Biocept
9.2.1.1. Company Overview
9.2.1.2. Financial Performance
9.2.1.3. Product Portfolio
9.2.1.4. Collaborations
 
9.2.2. Exosome Diagnostics
9.2.2.1. Company Overview
9.2.2.2. Product Portfolio
9.2.2.3. Collaborations
 
9.2.4. Genomic Health
9.2.4.1. Company Overview
9.2.4.2. Financial Performance
9.2.4.3. Product Portfolio
9.2.4.4. Collaborations
 
9.2.5. Guardant Health
9.2.5.1. Company Overview
9.2.5.2. Product Portfolio
9.2.5.3. Collaborations
9.2.6. Qiagen
9.2.6.1. Company Overview
9.2.6.2. Financial Performance
9.2.6.3. Product Portfolio
9.2.6.4. Collaborations
 
9.2.7. Trovagene
9.2.7.1. Company Overview
9.2.7.2. Financial Performance
9.2.7.3. Product Portfolio
9.2.7.4. Collaborations
 
9.3. Companies with Focus on Other Non-Invasive Diagnostic Techniques
9.3.1. bioMérieux
9.3.1.1. Company Overview
9.3.1.2. Financial Performance
9.3.1.3. Product Portfolio
9.3.1.4. Collaborations
 
9.3.2. Cepheid
9.3.2.1. Company Overview
9.3.2.2. Financial Performance
9.3.2.3. Product Portfolio
9.3.2.4. Collaborations
 
9.3.3. DermTech
9.3.3.1. Company Overview
9.3.3.2. Product Portfolio
9.3.3.3. Collaborations
 
9.3.4. DiagnoCure
9.3.4.1. Company Overview
9.3.4.2. Financial Performance
9.3.4.3. Product Portfolio
9.3.4.4. Collaborations
 
9.3.5. Exact Sciences
9.3.5.1. Company Overview
9.3.5.2. Financial Performance
9.3.5.3. Product Portfolio
9.3.5.4. Collaborations
 
9.3.7. Pacific Edge
9.3.7.1. Company Overview
9.3.7.2. Financial Performance
9.3.7.3. Product Portfolio
9.3.7.4. Collaborations
 
10. CONCLUSION
10.1. Improved Cancer Detection and Patient Care: A Growing Necessity
10.2. Introduction of Sophisticated Molecular Diagnostics: A Solution to the Existing Unmet Need
10.3. Liquid Biopsy: The Potential Replacement to Invasive Techniques
10.4. Other Non-Invasive Tests: Further Enhancing the Cancer Diagnostics Portfolio
10.5 With Liquid Biopsy at the Forefront, Non-Invasive Cancer Diagnostics Expected to Emerge as a Multi-Billion Dollar Market
 
11. INTERVIEW TRANSCRIPTS
11.1. Christer Ericsson, Chief Scientific Officer, iCellate AB
11.2. Philippe Nore, CEO and Co-founder, MiNDERA Corporation
11.3. Dr. Jake Micallef, Chief Scientific Officer, VolitionRx
 
12. APPENDIX 1: TABULATED DATA
 
13. APPENDIX 2: LIST OF COMPANIES AND ORGANISATIONS
 
 
Figure 3.1 Worldwide Incidence: Distribution by Type of Cancer
 
Figure 3.2 Lung Cancer: Estimated New Cases in 2015 (in’000s)
 
Figure 3.3 Breast Cancer: Estimated New Cases in 2015 (in ‘000s)
 
Figure 3.4 Colorectal Cancer: Estimated New Cases in 2015 (in ‘000s)
 
Figure 3.5 Factors Determining Useful Cancer Screening
 
Figure 3.6 Conventional Cancer Diagnosis Methods
 
Figure 3.7 Needle Biopsy and Open Biopsy: Demerits
 
Figure 4.1 Broad Categories of Non-Invasive Cancer Screening and Diagnostics
 
Figure 4.2 Types of Diagnostic Imaging
 
Figure 4.3 Types of Screening Assays
 
Figure 4.4 Types of Advanced Non-Invasive Approaches
 
Figure 5.1 Liquid Biopsy: Distribution by Type of Analysis
 
Figure 5.2 Liquid Biopsy: Distribution by Sample Source
 
Figure 5.3 Liquid Biopsy: Distribution by Indication
 
Figure 5.4 Liquid Biopsy: Distribution by Region
 
Figure 5.5 Other Non-Invasive Tests: Distribution by Sample Source
 
Figure 5.6 Other Non-Invasive Tests: Distribution by Indication
 
Figure 5.7 Other Non-Invasive Tests: Distribution by Region
 
Figure 6.1 Circulating Biomarkers for Cancer
 
Figure 6.2 ApoStream® Technology: Advantages
 
Figure 6.3 BioFluidica CTC Isolation System Workflow
 
Figure 6.4 BioFluidica System: Advantages
 
Figure 6.5 CELLSEARCH® System: Basic Steps
 
Figure 6.6 CELLSEARCH® System Workflow
 
Figure 6.7 LiquidBiopsy® Workflow
 
Figure 6.8 LiquidBiopsy® and Ion Torrent PGM Workflow Components
 
Figure 6.9 Parsortix System Workflow
 
Figure 6.10 ViewRNA CTC Platform Workflow
 
Figure 6.11 iCellate® Workflow
 
Figure 8.1 Non-Invasive Cancer Diagnostic Market (USD Million), Short Term, Base Case, 2015-2022
 
Figure 8.2 Non-Invasive Cancer Diagnostic Market (USD Million), Mid-Long Term, Base Case, 2022-2030
 
Figure 8.3 Liquid Biopsy Market (USD Million), Short Term, Base Case, 2015-2022
 
Figure 8.4 Liquid Biopsy Market (USD Million), Mid-Long Term, Base Case, 2022-2030
 
Figure 8.5 Prostate Cancer Liquid Biopsy Market (USD Million)
 
Figure 8.6 Breast Cancer Liquid Biopsy Market (USD Million)
 
Figure 8.7 Colorectal Cancer Liquid Biopsy Market (USD Million)
 
Figure 8.8 Lung Cancer Liquid Biopsy Market (USD Million)
 
Figure 8.9 Non-Invasive Cancer Diagnostics Market: Regional Analysis, 2022
 
Figure 8.10 Non-Invasive Cancer Diagnostics Market: Regional Analysis, 2030
 
Figure 9.1 Biocept Revenues, 2012- H1 2015 (USD Million)
 
Figure 9.2 Genomic Health Revenues, 2010- H1 2015 (USD Million)
 
Figure 9.3 Qiagen Revenues, 2010-Q1 2015 (USD Billion)
 
Figure 9.4 Qiagen Revenues, Q1 2015, Distribution by Business Segments (Share in %)
 
Figure 9.5 Trovagene Revenues, 2010-Q1 2015 (USD Million)
 
Figure 9.6 bioMérieux Revenues, 2011-Q1 2015 (EUR Billion)
 
Figure 9.7 bioNexia® FOB versus Guaiac Based Tests: Sensitivity for Positive Results
 
Figure 9.8 Cepheid Revenues, 2010- H1 2015 (USD Million)
 
Figure 9.9 Cepheid Revenues: Distribution by Type of Sales, 2014 (USD Million)
 
Figure 9.10 DiagnoCure Revenues, 2010-H1 2015 (USD Million)
 
Figure 9.11 Exact Sciences Revenues, 2010-HI 2015 (USD Million)
 
Figure 9.12 Pacific Edge Revenues, 2010-2014 (USD Million)
 
Figure 9.13 Cxbladder®: Biomarker Genes
 
Figure 10.1 Non-Invasive Cancer Diagnostic Market (USD Million), 2015, 2022 and 2030
 
 
Table 3.1 Survival on Early Diagnosis of Cancer
 
Table 3.2 Cost of Biopsy for Different Cancer Indications
 
Table 3.3 Common Endoscopic Procedures
 
Table 4.1 Examples of Tumour Markers
 
Table 5.1 Non-Invasive Cancer Diagnostics: Liquid Biopsy Tests
 
Table 5.2 Non-Invasive Cancer Diagnostics: Liquid Biopsy Technologies
 
Table 5.3 Non-Invasive Cancer Diagnostics: Liquid Biopsy Systems/ Instruments
 
Table 5.4 Non-Invasive Cancer Diagnostics: Other Screening and Diagnostic Tests
 
Table 6.1 Aspects of Biopsies versus Liquid Biopsies
 
Table 6.2 Liquid Biopsy Based Diagnostics: Example List
 
Table 6.3 Comparison between ApoStream CTC Test and CELLSEARCH® CTC Test
 
Table 6.4 ApoCell: Funding Instances
 
Table 6.5 Comparison of the Clinical Sensitivity of BioFluidica Technology and CELLSEARCH® Technology
 
Table 6.6 CELLSEARCH® CTC Test: Cut-offs For Disease Prognosis
 
Table 6.7 CynvenioBiosystems: Funding Rounds
 
Table 6.8 ANGLE: Funding Rounds
 
Table 6.9 IVD CTC Tests: Potential Indications
 
Table 6.10 IVDiagnostics: Funding Rounds
 
Table 7.1 Sensitivity/Specificity: Individual Technologies versus Combination
 
Table 7.2 Imaging Based Diagnostics: Example List
 
Table 7.3 Biomarker and Nucleosome Detection Based Diagnostics: Example List
 
Table 7.4 Skin Lesion Based Diagnostics: Example List
 
Table 7.5 Diagnostic Breath Testing Devices: Example List
 
Table 8.1 Liquid Biopsy for Initial Diagnosis: Market Forecast Assumptions
 
Table 8.2 Liquid Biopsy for Recurrence Monitoring: Market Forecast Assumptions
 
Table 8.3 Liquid Biopsy for Patient Monitoring: Market Forecast Assumptions
 
Table 9.1 Q1Aamp® Circulating Nucleic Acid Kit: Specifications
 
Table 9.2 VIDAS® Tumour Markers: Specifications
 
Table 9.3 VIDAS® Tumour Markers, 2011-2014
 
Table 9.4 Xpert® HPV: Comparative Clinical Performance
 
Table 9.5 ImmunoCyt™/uCYT+™: Comparison with Other Urinary Cancer Biomarker Assays
 
Table 9.6 PCA3 Test: Launch Years for Respective Geographies
 
Table 12.1 Worldwide Incidence: Distribution by Type of Cancer
 
Table 12.2 Lung Cancer: Estimated New Cases in 2015 (in ‘000s)
 
Table 12.3 Breast Cancer: Estimated New Cases in 2015 (in ‘000s)
 
Table 12.4 Colorectal Cancer: Estimated New Cases in 2015 (in ‘000s)
 
Table 12.5 Liquid Biopsy: Distribution by Type of Analysis
 
Table 12.6 Liquid Biopsy: Distribution by Sample Source
 
Table 12.7 Liquid Biopsy: Distribution by Indication
 
Table 12.8 Liquid Biopsy: Distribution by Region
 
Table 12.9 Other Non-Invasive Diagnostic Tests: Distribution by Sample Source
 
Table 12.10 Other Non-Invasive Diagnostic Tests: Distribution by Indication
 
Table 12.11 Other Non-Invasive Diagnostic Tests: Distribution by Region
 
Table 12.12 Non-Invasive Cancer Diagnostic Market (USD Million), Short Term, Base Case, 2015-2022
 
Table 12.13 Non-Invasive Cancer Diagnostic Market (USD Million), Mid-Long Term, Base Case, 2022-2030
 
Table 12.14 Non-Invasive Cancer Diagnostic Market (USD Million), Short Term, Optimistic Case, 2015-2022
 
Table 12.15 Non-Invasive Cancer Diagnostic Market (USD Million), Mid-Long Term, Optimistic Case, 2022-2030
 
Table 12.16 Non-Invasive Cancer Diagnostic Market (USD Million), Short Term, Conservative Case, 2015-2022
 
Table 12.17 Non-Invasive Cancer Diagnostic Market (USD Million), Mid-Long Term Conservative Case, 2022-2030
 
Table 12.18 Liquid Biopsy Market (USD Million), Short Term, Base Case, 2015-2022
 
Table 12.19 Liquid Biopsy Market (USD Million), Mid-Long Term, Base Case, 2022-2030
 
Table 12.20 Liquid Biopsy Market (USD Million), Short Term, Optimistic Case, 2015-2022
 
Table 12.21 Liquid Biopsy Market (USD Million), Mid-Long Term, Optimistic Case, 2022-2030
 
Table 12.22 Liquid Biopsy Market (USD Million), Short Term, Conservative Case, 2015-2022
 
Table 12.23 Liquid Biopsy Market (USD Million), Mid Long Term, Conservative Case, 2022-2030
 
Table 12.24 Prostate Cancer Liquid Biopsy Market (USD Million)
 
Table 12.25 Breast Cancer Liquid Biopsy Market (USD Million)
 
Table 12.26 Colorectal Cancer Liquid Biopsy Market (USD Million)
 
Table 12.27 Lung Cancer Liquid Biopsy Market (USD Million)
 
Table 12.28 Non-Invasive Cancer Diagnostics Market: Regional Analysis, 2022
 
Table 12.29 Non-Invasive Cancer Diagnostics Market: Regional Analysis, 2030
 
Table 12.30 Biocept Revenues, 2012- H1 2015 (USD Million)
 
Table 12.31 Genomic Health Revenues, 2010- H1 2015 (USD Million)
 
Table 12.32 Qiagen Revenues, 2010-Q1 2015 (USD Billion)
 
Table 12.33 Qiagen Revenues, Q1 2015, Split by Business Segments (Share in %)
 
Table 12.34 Trovagene Revenues, 2010-Q1 2015 (USD Million)
 
Table 12.35 bioMérieux Revenues, 2011-Q1 2015 (EUR Billion)
 
Table 12.36 bioNexia® FOB versus Guaiac Based Tests: Sensitivity for Positive Results
 
Table 12.37 Cepheid Revenues, 2010- H1 2015 (USD Million)
 
Table 12.38 Cepheid Revenues: Distribution by Type of Sales, 2014 (USD Million)
 
Table 12.39 DiagnoCure Revenues, 2010-H1 2015 (USD Million)
 
Table 12.40 Exact Sciences Revenues, 2010-HI 2015 (USD Million)
 
Table 12.41 Pacific Edge Revenues, 2010-2014 (USD Million)
 
Table 12.42 Lung Cancer Liquid Biopsy Market (USD Million), 2015, 2022, 2030
 

 

The following companies and organisations have been mentioned in this report.

  1. A&G Pharmaceutical
  2. Accelerate Brain Cancer Cure
  3. AcousysBiodevices
  4. Addario Lung Cancer Medical Institute
  5. Admera Health
  6. AdnaGen
  7. Affymetrix
  8. Agena Bioscience
  9. Almac Group
  10. America’s Choice Provider Network
  11. American Lung Association
  12. Angle plc
  13. Anixa Diagnostics Corporation
  14. ApoCell
  15. ARUP Laboratories
  16. Astellas Pharma
  17. AstraZeneca
  18. Astute Medical
  19. Aviva Biosciences
  20. Barts Cancer Institute
  21. Bayer Healthcare
  22. BC Cancer Agency
  23. BGI Tech Solutions
  24. Biocartis
  25. Biocept
  26. Biodesix
  27. BioFluidica
  28. bioMérieux
  29. Biosense Medical
  30. Biotype Diagnostics
  31. BioView
  32. Boreal Genomics
  33. Brigham and Women's Hospital
  34. Canopus Bioscience
  35. Catholic Health Initiatives Center
  36. Clarient
  37. ClearbridgeBioMedics
  38. Clovis Oncology
  39. CollabRx
  40. Columbia University
  41. Comprehensive Cancer Center
  42. COPAN
  43. CreatvMicroTech
  44. Cubist Pharmaceuticals
  45. CynvenioBiosystems
  46. CytoTrack
  47. CytoLumina Technologies
  48. Dana Farber Cancer Institute
  49. Datar Generics
  50. Denovo Sciences
  51. DermTech
  52. DiagnoCure
  53. Diagnologix
  54. Digene Corporation
  55. Drug Response Dx
  56. EKF Molecular Diagnostics
  57. Eli Lilly
  58. Epic Sciences
  59. Epigenomics
  60. European Medical Network for Translational Research in Ovarian Cancer
  61. Exact Sciences
  62. Exosome Diagnostics
  63. Exosomics Siena
  64. Fairview Health Services
  65. FedMed
  66. Flatiron Health
  67. Fluxion Biosciences
  68. Foundation Medicine
  69. Fraunhofer Institute for Cell Therapy and Immunology
  70. Genomic Health
  71. Genoptix
  72. Gensignia
  73. GlaxoSmithKline
  74. Guangdong Medical College
  75. Guardant Health
  76. HainLifescience
  77. HansaBioMed
  78. Healthscope Pathology
  79. Hitachi High-Technologies
  80. iCellate Medical
  81. Illumina
  82. Incyte Genomics
  83. Inivata
  84. Insight Genetics
  85. Ipsen
  86. Ironwood Pharmaceuticals
  87. IVDiagnostics
  88. Janssen Diagnostics
  89. OHSU Knight Cancer Institute
  90. Labcorp
  91. London Health Sciences Centre
  92. Louisiana State University
  93. Massachusetts General Hospital
  94. Mayo Clinic
  95. Mayo Medical Laboratory Network
  96. MD Anderson Cancer Center
  97. MDx Health
  98. Medical University of Vienna
  99. MELA Sciences
  100. Merck Serono
  101. MiNDERA
  102. MolecularMD
  103. Molecular Pathology Laboratory Network
  104. Natera
  105. National Cancer Institute
  106. NeoGenomics Laboratory
  107. Novartis
  108. Novigenix
  109. Ortho Biotech Oncology Research & Development
  110. Pacific Edge
  111. Palex Medical
  112. Pathway Genomics
  113. PathQC
  114. Personal Genome Diagnostics 
  115. Promega Corporation
  116. Prostate Cancer Foundation
  117. Qiagen
  118. Quanterix
  119. Quest Diagnostics
  120. RainDance Technologies
  121. Rarecells Diagnostics
  122. RareCyte
  123. Roche
  124. Rosetta Genomics
  125. Roswell Park Cancer Institute
  126. Royal Philips Electronics
  127. Rutgers New Jersey Medical School
  128. SAIC-Frederick
  129. Sarah Cannon Research Institute
  130. ScheBo
  131. ScreenCell
  132. Siemens
  133. Sequenom
  134. Shimadzu
  135. Shuwen Biotech
  136. Signal Genetics
  137. Signature Diagnostics
  138. Silicon Biosystems
  139. SIMSYS
  140. Skyline Diagnostics
  141. Southern California Permanente Medical Group
  142. SRI International
  143. StableBody Technologies
  144. Stiefel Laboratories
  145. Strand Life Sciences
  146. SysmexInostics
  147. Tan TockSeng Hospital
  148. Targeted Diagnostics & Therapeutics
  149. Technion-Israel Institute of Technology
  150. The Valld’Hebron Institute of Oncology
  151. Thermo Fisher Scientific
  152. Thomas Jefferson University
  153. Tokai Pharmaceuticals
  154. Transgenomic
  155. Trovagene
  156. Tumour Bank Ovarian Cancer Network
  157. University of California
  158. University of Dusseldorf
  159. University of Michigan
  160. University of Nijmegen
  161. University of Southern California
  162. University of Texas
  163. Uppsala BIO
  164. Vancouver Prostate Centre
  165. Veolia Environnement
  166. Veracyte
  167. Veridex
  168. Viatar CTC Solutions
  169. Virginia Commonwealth University
  170. Vitatex
  171. VolitionRx

 

You may also like

Copyright © Roots Analysis. All Rights Reserved.
website security